GSK to acquire clinical-stage biopharmaceutical company Affinivax, Inc.
- Details
- Category: GlaxoSmithKline
![GlaxoSmithKline GlaxoSmithKline](/images/logo/gsk.png)
FDA approves Roche’s Evrysdi for use in babies under two months with spinal muscular atrophy (SMA)
- Details
- Category: Roche
![Roche Roche](/images/logo/roche.png)
Roche develops unique PCR tests to detect the monkeypox virus
- Details
- Category: Roche
![Roche Roche](/images/logo/roche.png)
Vaxzevria approved in the EU as third dose booster against COVID-19
- Details
- Category: AstraZeneca
![AstraZeneca AstraZeneca](/images/logo/astrazeneca.png)
Healthcare professionals can now use Vaxzevria as a third dose booster in patients previously given a primary vaccine schedule of either Vaxzevria or an EU-approved mRNA COVID-19 vaccine.
Pfizer 'aunches 'An Accord for a Healthier World' to improve health equity for 1.2 billion people living in 45 lower-income countries
- Details
- Category: Pfizer
![Pfizer Pfizer](/images/logo/pfizer.png)
Roche enters partnership with the Global Fund to support low- and middle-income countries in strengthening critical diagnostics infrastructure
- Details
- Category: Roche
![Roche Roche](/images/logo/roche.png)
Nearly 700,000 US hospitalizations and 110,000 deaths prevented from the Pfizer-BioNTech COVID-19 vaccine
- Details
- Category: Business
The profound health and economic impact of the Pfizer-BioNTech vaccine during its first year of rollout in the US is described in detail in a new study in the peer-reviewed Journal of Medical Economics.
It is estimated that in 2021 the vaccine, the most widely used against COVID-19 in the US, prevented 8.7 million symptomatic cases of the virus, as well as 690,000 hospitalizations and more than 110,000 deaths.
More Pharma News ...
- Pfizer and BioNTech provide update on COVID-19 vaccine supply agreement with European Commission
- Roche pledges to extend commitment to the World Federation of Hemophilia Humanitarian Aid Program to 2028
- Pfizer to acquire Biohaven Pharmaceuticals
- Foundation S: Sanofi's new philanthropic spearhead
- Pfizer shares top-line results from Phase 2/3 EPIC-PEP study of PAXLOVID™ for post-exposure prophylactic use
- SK bioscience and GSK's adjuvanted COVID-19 vaccine candidate meets coprimary objectives in a phase III study
- Pfizer and Biohaven's VYDURA® (rimegepant) granted first ever marketing authorization by European Commission for both acute treatment of migraine and prophylaxis of episodic migraine